The 2023 Consolidated Appropriations Act, which was signed into law on December 29, 2022, includes a provision that eliminates the DATA (Drug Addiction Treatment Act) waiver. As a result, any DEA-registered provider can now prescribe buprenorphine just as they would any other controlled substance, with no x-waiver needed, effective immediately. Additionally, the patient caps for buprenorphine are also eliminated, which means that providers are able to treat as many patients with buprenorphine as they deem necessary.